Jardiance Cost in Missouri 2026: Cash Price, Medicaid, Compounding, and Savings Options

What Does Jardiance Actually Cost in Missouri in 2026?

The retail cash price for a 30-day supply of Jardiance in Missouri runs about $680 per month in 2026, matching the Boehringer Ingelheim and Eli Lilly list price. That figure applies whether you fill at a CVS in Kansas City, a Walgreens in St. Louis, or an independent pharmacy in Springfield. Without insurance or a savings program, that adds up to $8,160 per year, a figure most Missouri households cannot sustain long-term.

The gap between list price and actual cost paid has widened in recent years because pharmacy benefit managers (PBMs) negotiate rebates with manufacturers after the list price is set. Those rebates rarely flow directly to cash-paying patients, which means the person at the pharmacy counter often pays the highest possible price.

Prices vary slightly based on pharmacy and any generic contracts in place. Empagliflozin does not yet have an FDA-approved generic as of mid-2025, which keeps the cash price high across all Missouri retail chains [1]. The FDA has approved empagliflozin tablets (brand name Jardiance) for three distinct indications: type 2 diabetes mellitus, heart failure with reduced and preserved ejection fraction, and chronic kidney disease [2].

Telehealth platforms operating in Missouri can legally prescribe empagliflozin after a clinically appropriate evaluation, a particularly useful option for patients in rural Missouri counties where endocrinology and cardiology access is limited.

Missouri Medicaid Coverage for Jardiance: What the State Formulary Actually Says

Missouri Medicaid does not cover Jardiance for type 2 diabetes as a stand-alone indication. Patients whose only qualifying diagnosis is T2D should expect a denial on the Missouri HealthNet formulary.

The picture is more nuanced for heart failure and chronic kidney disease. Missouri HealthNet may cover empagliflozin for HF and CKD indications under the appropriate diagnosis codes, but coverage is not guaranteed and prior authorization requirements apply. Providers must document the qualifying diagnosis, typically a confirmed eGFR below 45 mL/min/1.73 m² for the CKD pathway or a left ventricular ejection fraction below 40% for the HFrEF pathway.

Patients enrolled in Missouri Medicaid managed care plans (Centene/WellCare, UnitedHealthcare Community Plan, and others operating in the state) may face plan-specific formulary tiers that differ from the base HealthNet formulary. Calling the managed care plan directly to request a formulary exception is often worth the 30-minute effort, especially if a prescriber provides a letter of medical necessity.

The American Diabetes Association's 2024 Standards of Care note that "SGLT2 inhibitors with proven cardiovascular benefit are recommended for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c" [3]. That language can support a medical-necessity argument to a Medicaid managed care plan.

For Missouri residents on fee-for-service Medicaid without a managed care overlay, the preferred drug list should be checked through the Missouri HealthNet Division directly, as it is updated quarterly.

Is Compounded Empagliflozin Legal in Missouri?

Yes, compounded empagliflozin is legal in Missouri when prepared by a licensed 503A pharmacy operating under state board of pharmacy oversight and federal USP standards.

A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. Missouri does not have a state-level prohibition on compounding SGLT2 inhibitors, which means a prescriber in Missouri can send a compounded empagliflozin prescription to a licensed 503A compounding pharmacy and the patient can receive it legally [4].

The key regulatory caveat is that 503A pharmacies cannot compound a drug that is a copy of a commercially available product unless there is a clinical difference, such as a custom dose, a different vehicle, or a patient-specific allergy accommodation. Prescribers who write for compounded empagliflozin typically specify a dose not commercially available (for example, 5 mg, 15 mg, or a combination formula) or document a clinical rationale.

503B outsourcing facilities, which manufacture in bulk without patient-specific prescriptions, operate under different FDA oversight. Empagliflozin is not currently on the FDA's list of shortage drugs, so 503B bulk compounding of empagliflozin carries higher regulatory risk [5]. Most Missouri patients accessing compounded empagliflozin will go through a 503A pharmacy, not a 503B facility.

Pricing for compounded empagliflozin from 503A pharmacies varies widely, from roughly $40 to $120 per month depending on dose, excipients, and the compounding pharmacy's fee structure. That represents a substantial reduction from the $680 retail list price.

The HealthRX clinical team uses the following decision framework when evaluating compounded empagliflozin for Missouri patients: (1) Confirm the patient does not have commercial insurance that covers brand Jardiance at a net cost below $50/month after savings card application. (2) Verify the prescribing clinician documents a clinical rationale for the compounded dose. (3) Confirm the 503A pharmacy holds a current Missouri pharmacy license and a compounding accreditation (PCAB preferred). (4) Assess the patient's cardiovascular and renal risk profile to ensure the SGLT2 mechanism is appropriate before writing. (5) Schedule a follow-up lab panel (BMP, urinalysis) at 4 to 6 weeks to check for UTI, DKA risk, or eGFR shift.

Why Jardiance Costs What It Does: The Pricing History

Empagliflozin launched in the U.S. in 2014 at a price point competitive with other branded SGLT2 inhibitors, including dapagliflozin (Farxiga) and canagliflozin (Invokana). Since then, the list price has climbed steadily while net prices paid by large commercial insurers have been buffered by manufacturer rebates.

The Boehringer Ingelheim and Eli Lilly partnership markets Jardiance jointly. Their co-promotion agreement, active since 2014, means two large pharmaceutical companies share the cost of maintaining pricing power on the molecule. No FDA-approved generic empagliflozin tablet existed as of mid-2025. Patent protection on the core molecule and on the formulation extends through the late 2020s in the U.S., though litigation could alter that timeline.

Insulin pricing legislation and some state-level drug pricing transparency laws have not directly controlled SGLT2 inhibitor prices. Missouri has not enacted a state-specific SGLT2 price cap as of 2025.

Clinical Outcomes That Justify the Cost: EMPA-REG OUTCOME and Beyond

The cost conversation around Jardiance is inseparable from its outcomes data. Before empagliflozin, most glucose-lowering drugs were approved based on glycemic endpoints alone. EMPA-REG OUTCOME changed the standard.

In EMPA-REG OUTCOME (N=7,020 patients with T2D and established cardiovascular disease), empagliflozin 10 mg or 25 mg once daily reduced the primary three-point MACE outcome (CV death, non-fatal MI, non-fatal stroke) by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority and P=0.04 for superiority) [6]. More striking was the 38% relative reduction in cardiovascular death (HR 0.62 to 95% CI 0.49 to 0.77).

The EMPEROR-Reduced trial (N=3,730 patients with HFrEF, mean ejection fraction 27.2%) showed empagliflozin 10 mg once daily reduced the composite of CV death or hospitalization for heart failure by 25% (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) compared to placebo [7]. EMPEROR-Preserved (N=5,988 patients with HFpEF) demonstrated a 21% reduction in the same composite endpoint, making empagliflozin the first glucose-lowering drug to show benefit in HFpEF [8].

The EMPA-KIDNEY trial (N=6,609 patients with CKD, median eGFR 37.3 mL/min/1.73 m²) showed empagliflozin 10 mg reduced progression of kidney disease or CV death by 28% (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [9]. These four large trials collectively explain why major cardiology and nephrology guidelines now recommend SGLT2 inhibitors as a first-line add-on for qualifying patients, independent of glycemic targets.

The American Heart Association's 2022 Heart Failure Guidelines state that "SGLT2 inhibitors are recommended to reduce HF hospitalizations and cardiovascular death in patients with symptomatic chronic HF" with a Class I, Level of Evidence A recommendation [10]. When a drug carries Class I evidence across four large randomized controlled trials, its cost calculation changes for payers and for patients trying to make the case for coverage.

How Commercial Insurance Covers Jardiance in Missouri

Commercial insurance coverage for Jardiance in Missouri depends on the specific plan formulary and the patient's diagnosis code. Employer-sponsored plans, ACA marketplace plans, and Medicare Part D each handle coverage differently.

Employer-sponsored plans. Most large employer plans in Missouri that use a national PBM (Express Scripts, CVS Caremark, OptumRx) place Jardiance on Tier 3 or Tier 4. At Tier 3, the typical patient cost share runs $80 to $150 per month after deductible. At Tier 4 specialty tier, cost share can reach 25% to 33% coinsurance, which at a $680 list price means $170 to $224 per fill.

ACA marketplace plans. Missouri marketplace plans sold through healthcare.gov vary significantly by carrier. Anthem, Cigna, and Centene all operate in Missouri marketplace segments. Coverage and tier placement differ by metal level and county.

Medicare Part D. Jardiance appears on most Part D formularies in Missouri at Tier 3 or Tier 4. In 2025 and 2026, the Medicare Prescription Drug Negotiation program created under the Inflation Reduction Act may affect Part D pricing for some drugs, though empagliflozin's status under direct negotiation has not been confirmed as of this writing.

Regardless of plan, Missouri patients with commercial insurance should apply the Boehringer Ingelheim and Lilly savings card before comparing costs to a compounded alternative.

The Boehringer Ingelheim / Lilly Savings Card: Real Numbers for Missouri Patients

The Jardiance savings card is the single most impactful cost-reduction tool for commercially insured Missouri patients. Eligible patients with private or employer-sponsored insurance can pay as little as $10 per month for a 30-day supply. The program caps the manufacturer's contribution at $150 per fill (a maximum of $1,800 per year in savings) [11].

The savings card does not apply to patients enrolled in Medicare, Medicaid, or any other federal or state government health program. Missouri HealthNet enrollees are explicitly excluded.

To use the card:

1. Visit jardiance.com to download the savings card or receive a card number by text.
2. Present the card alongside your insurance card at any Missouri retail pharmacy.
3. The manufacturer contribution is applied after your insurance processes the claim.

Some patients with high-deductible health plans find that the savings card reduces their out-of-pocket cost even before meeting the deductible, because the card offsets the full contracted price the PBM would otherwise collect. Confirm this with your specific pharmacy and plan before assuming the card works in the deductible period.

GoodRx and similar discount programs do not typically beat the Jardiance savings card for commercially insured patients, but they can reduce the cash price for uninsured patients to roughly $580 to $620 per month at Missouri pharmacies, still well above a compounded alternative.

Telehealth Prescribing of Jardiance in Missouri

Missouri permits telehealth prescribing of non-controlled medications, including empagliflozin, through a synchronous audio-video evaluation. The Missouri Board of Healing Arts has not imposed additional restrictions on telehealth prescribing of SGLT2 inhibitors beyond standard prescribing standards of care.

A telehealth prescriber in Missouri must establish a valid patient-provider relationship, review relevant lab data (renal function, HbA1c, or BNP as appropriate to the indication), and confirm no contraindications before writing for empagliflozin. Empagliflozin is contraindicated in patients with eGFR below 20 mL/min/1.73 m² for the CKD indication, and use below eGFR 30 is generally not recommended for glycemic benefit [2].

Telehealth visits for Jardiance prescribing typically cost $75 to $150 at HealthRX and similar platforms, and a clinician can often handle lab review, prescription issuance, and savings card enrollment in a single 20-minute appointment. For patients in rural Missouri counties, this is often faster and cheaper than driving to an endocrinology clinic with a 3-to-6-month wait.

Practical Cost-Reduction Flowchart for Missouri Patients in 2026

Choosing the lowest-cost path for empagliflozin in Missouri follows a straightforward sequence. Start by checking insurance status, then apply cost-reduction tools in order:

Step 1: Do you have commercial insurance? Yes. Apply the Jardiance savings card immediately. Most commercially insured Missouri patients will pay $10 to $50 per month.

Step 2: Does your commercial plan cover Jardiance at all? No. Request a formulary exception with a provider letter citing the ADA 2024 Standards of Care or the relevant ACC/AHA guideline. If denied, move to Step 3.

Step 3: Are you on Missouri Medicaid? Check the HF or CKD diagnosis pathway. If T2D is your only indication, coverage is unlikely. Move to Step 4.

Step 4: Cash-pay options. Compare GoodRx or similar coupon tools (expect $580 to $620/month) with a licensed 503A compounding pharmacy (expect $40 to $120/month for a custom dose with documented clinical rationale). Compounding requires a valid prescription with documented clinical necessity.

Step 5: Apply for Patient Assistance. Boehringer Ingelheim's Cares Foundation offers free or low-cost Jardiance to qualifying uninsured patients with household income below 400% of the federal poverty level. Applications are processed through bi-pharma-assistance.com or directly through the Cares Foundation program.

Safety Considerations Missouri Patients Should Know Before Starting

Empagliflozin works by blocking sodium-glucose cotransporter-2 in the proximal tubule of the kidney, increasing urinary glucose excretion by roughly 70 to 80 grams per day and reducing blood pressure by 2 to 3 mmHg through osmotic diuresis [12].

Common side effects include genital mycotic infections (occurring in about 6.4% of women and 3.1% of men in EMPA-REG OUTCOME) and urinary tract infections. Rarely, euglycemic diabetic ketoacidosis can occur, particularly in patients fasting before surgery or in patients with type 1 diabetes (for whom empagliflozin is not FDA-approved) [2].

The FDA added a boxed warning about the risk of Fournier's gangrene (necrotizing fasciitis of the perineum), an extremely rare but life-threatening infection, to the labeling of all SGLT2 inhibitors. Patients should be counseled to report perineal pain, tenderness, or swelling immediately.

Volume depletion can be significant in elderly Missouri patients or those on loop diuretics. Baseline renal function, blood pressure, and concomitant diuretic dose should be reviewed before starting.

Missouri patients who start empagliflozin through a telehealth platform should complete a basic metabolic panel and urinalysis at baseline and again at 4 to 6 weeks after initiation, particularly if their eGFR is below 60 mL/min/1.73 m².